Protocol No.: V221-027; A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with Alternative Manufacturing Process (AMP)

Project: Other project

StatusFinished
Effective start/end date6/21/126/20/14

Funding

  • Merck Sharp & Dohme Corporation: $45,700.00